Search
                    Honolulu, HI Paid Clinical Trials
A listing of 204  clinical trials  in Honolulu, HI  actively recruiting volunteers for paid trials and research studies in various therapeutic areas.
            121 - 132 of 204
        
                There are currently 204 clinical trials in Honolulu, Hawaii looking for participants to engage in research studies. Trials are conducted at various facilities, including Kapiolani Medical Center for Women and Children, Queen's Medical Center, University of Hawaii Cancer Center and Straub Clinic and Hospital. Whether you're a healthy volunteer looking to participate in paid medical research or seeking trials related to a specific condition, the city provides a diverse range of opportunities near you. 
            
                                        Featured Trial
                
                Healthy Participants Needed (Colonoscopy + Cancer Screening)
            
        Recruiting
            
        Earn $325 - $475 in electronic payment card compensation for your time and effort by participating in a clinical study to develop a blood test that may one day help screen for colon cancer. Take a quick quiz to see if you qualify.
    
    
                            Conditions: 
                                    
        
            
                        Healthy
                    
                                    
                        Healthy Volunteers
                    
                                    
                        Healthy Subjects
                    
                                    
                        Healthy Volunteer
                    
                                    
                        Healthy Participants
                    
                                    Featured Offer
                
                Lose Weight with GLP-1 Medications
            
        Recruiting
            
        Policy Lab has partnered with OnlineSemaglutide.org to offer trusted access to semaglutide and other GLP-1 medications, including generic alternatives to Ozempic® and Wegovy®. 
GLP-1 medications are scientifically backed to help individuals achieve significant weight loss—on average, 15-20% of body weight within a year.
As a valued user, you’re eligible for $50 off your first program with code policy-lab-50.
    GLP-1 medications are scientifically backed to help individuals achieve significant weight loss—on average, 15-20% of body weight within a year.
As a valued user, you’re eligible for $50 off your first program with code policy-lab-50.
                            Conditions: 
                                    
        
            
                        Overweight
                    
                                    
                        Overweight and Obesity
                    
                                    
                        Obesity
                    
                                    
                        Weight Loss
                    
                                    
                        Morbid Obesity
                    
                                    Featured Trial
                
                Stroke Clinical Study
            
        Recruiting
            
        A clinical study for people that suffer with Stroke
    
    
                            Conditions: 
                                    
        
            
                        Stroke
                    
                                    Featured Trial
                
                Chronic Kidney Disease (CKD) Clinical Study
            
        Recruiting
            
        A clinical study for people that suffer with Chronic Kidney Disease (CKD)
    
    
                            Conditions: 
                                    
        
            
                        Chronic Kidney Disease (CKD)
                    
                                    Featured Trial
                
                Ischemic heart disease (IHD) Clinical Study
            
        Recruiting
            
        A clinical study for people that suffer with Ischemic heart disease (IHD)
    
    
                            Conditions: 
                                    
        
            
                        Ischemic heart disease (IHD)
                    
                                    Featured Trial
                
                Cardiovascular Disease Clinical Study
            
        Recruiting
            
        A clinical study for people that suffer with Cardiovascular Disease
    
    
                            Conditions: 
                                    
        
            
                        Cardiovascular Disease
                    
                                    
                
                                    A Study to Evaluate Mavacamten Impact on Myocardial Structure in Participants With Symptomatic Obstructive Hypertrophic Cardiomyopathy
                                
            
            
        Recruiting
                            
            
                The purpose of this study is to evaluate the mavacamten impact on myocardial structure with cardiac magnetic resonance imaging (CMR) in adult participants with symptomatic obstructive hypertrophic cardiomyopathy (oHCM) \[New York Heart Association (NYHA) Functional Class II or III\].             
        
        
    Gender:
                ALL
            Ages:
                18 years and above
            Trial Updated:
                06/30/2025
            
            Locations: Local Institution - 0091, Honolulu, Hawaii         
        
        
            Conditions: Cardiomyopathy, Hypertrophic
        
            
        
    
                
                                    A Research Study to Look Into the Long-term Effect on Weight Loss of CagriSema in People With Obesity
                                
            
            
        Recruiting
                            
            
                This study will look at how well CagriSema helps people with obesity lose weight compared to a "dummy medicine". CagriSema is a new medicine developed by Novo Nordisk. CagriSema cannot yet be prescribed by doctors. The study has two parts: First part is called the main phase and will last for 2 years, and second part is called the extension phase and will last for 1 year. In the main phase participants will either get CagriSema or "dummy medicine". Which treatment participants get is decided by...  Read More             
        
        
    Gender:
                ALL
            Ages:
                18 years and above
            Trial Updated:
                06/27/2025
            
            Locations: East West Medical Research Institute_Honolulu, Honolulu, Hawaii         
        
        
            Conditions: Obesity
        
            
        
    
                
                                    A Randomized Study of XEN1101 Versus Placebo in Focal-Onset Seizures
                                
            
            
        Recruiting
                            
            
                The X-TOLE2 Phase 3 clinical trial is a randomized, double-blind, placebo-controlled study that will evaluate the clinical efficacy, safety and tolerability of XEN1101 administered as adjunctive therapy in focal-onset seizures.             
        
        
    Gender:
                ALL
            Ages:
                18 years and above
            Trial Updated:
                06/27/2025
            
            Locations: Hawaii Pacific Neuroscience, Honolulu, Hawaii         
        
        
            Conditions: Focal Onset Seizures
        
            
        
    
                
                                    A Study to Evaluate XEN1101 as Adjunctive Therapy in Primary Generalized Tonic-Clonic Seizures
                                
            
            
        Recruiting
                            
            
                This is a Phase 3, multicenter, randomized, double-blind, placebo-controlled study to evaluate the clinical efficacy, safety, and tolerability of XEN1101 administered as adjunctive treatment in primary generalized tonic-clonic seizures (PGTCS).             
        
        
    Gender:
                ALL
            Ages:
                12 years and above
            Trial Updated:
                06/27/2025
            
            Locations: Hawaii Pacific Neuroscience, Comprehensive Epilepsy Center, Honolulu, Hawaii         
        
        
            Conditions: Primary Generalized Tonic-Clonic Seizures
        
            
        
    
                
                                    Assessing Acceptability and Feasibiity of STI Self-swab Testing, to be Offered at the Time of Telemed Medication Abortion Provision
                                
            
            
        Recruiting
                            
            
                The goal of this interventional study is to provide more access to STI testing for patients who seek abortion care through telemedicine, particularly for those whose access to STI testing is otherwise limited. The main questions it aims to answer are:
What is the acceptability, feasibility, and utilization of self-collected STI screening at the time of telemedicine medication abortion provision?
How does the uptake of such a service among patients receiving telemedicine abortion care compare t...  Read More             
        
        
    Gender:
                FEMALE
            Ages:
                14 years and above
            Trial Updated:
                06/25/2025
            
            Locations: Queens Medical Center, 1004 Clinic POB1, Honolulu, Hawaii         
        
        
            Conditions: Sexually Transmitted Disease (STD), Gonorrhea, Chlamydia, Trichomonas Infection
        
            
        
    
                
                                    Comparing Radiation Therapy to Usual Care for Patients With High-Risk Bone Asymptomatic Metastases
                                
            
            
        Recruiting
                            
            
                This phase III trial compares the effect of adding radiation therapy to usual care on the occurrence of bone-related complications in cancer patients with high-risk bone metastases that are not causing symptoms (asymptomatic). High-risk bone metastases are defined by their location (including hip, shoulder, long bones, and certain levels of the spine), or size (2 cm or larger). These bone metastases appear to be at higher risk of complications such as fracture, spinal cord compression, and/or pa...  Read More             
        
        
    Gender:
                ALL
            Ages:
                18 years and above
            Trial Updated:
                06/25/2025
            
            Locations: Kaiser Permanente Moanalua Medical Center, Honolulu, Hawaii         
        
        
            Conditions: Metastatic Malignant Neoplasm in the Bone, Metastatic Malignant Solid Neoplasm
        
            
        
    
                
                                    Vismodegib, FAK Inhibitor GSK2256098, Capivasertib, and Abemaciclib in Treating Patients With Progressive Meningiomas
                                
            
            
        Recruiting
                            
            
                This phase II trial studies how well vismodegib, focal adhesion kinase (FAK) inhibitor GSK2256098, and capivasertib work in treating patients with meningioma that is growing, spreading, or getting worse (progressive). Vismodegib, FAK inhibitor GSK2256098, capivasertib, and abemaciclib may stop the growth of tumor cells by blocking some of the enzymes needed for cell growth.             
        
        
    Gender:
                ALL
            Ages:
                18 years and above
            Trial Updated:
                06/24/2025
            
            Locations: Kaiser Permanente Moanalua Medical Center, Honolulu, Hawaii         
        
        
            Conditions: Intracranial Meningioma, Recurrent Meningioma, NF2 Gene Mutation
        
            
        
    
                
                                    Testing the Use of the Usual Chemotherapy Before and After Surgery for Removable Pancreatic Cancer
                                
            
            
        Recruiting
                            
            
                This phase III trial compares perioperative chemotherapy (given before and after surgery) versus adjuvant chemotherapy (given after surgery) for the treatment of pancreatic cancer that can be removed by surgery (removable/resectable). Chemotherapy drugs, such as fluorouracil, irinotecan, leucovorin, and oxaliplatin, work in different ways to stop the growth of tumor cells, either by killing the cells, by stopping them from dividing, or by stopping them from spreading. Giving chemotherapy before...  Read More             
        
        
    Gender:
                ALL
            Ages:
                18 years and above
            Trial Updated:
                06/24/2025
            
            Locations: Queen's Medical Center, Honolulu, Hawaii  +1 locations         
        
        
            Conditions: Pancreatic Adenosquamous Carcinoma, Resectable Pancreatic Adenocarcinoma, Pancreatic Cancer
        
            
        
    
                
                                    Additional Support Program Via Text Messaging and Telephone-Based Counseling for Breast Cancer Patients Receiving Hormonal Therapy
                                
            
            
        Recruiting
                            
            
                This phase III trial compares an additional support program (text message reminders and/or telephone-based counseling) with usual care in making sure breast cancer patients take their endocrine therapy medication as prescribed (medication adherence). Medication adherence is how well patients take the medication as prescribed by their doctors, and good medical adherence is when patients take medications correctly. Poor medication adherence has been shown to be a serious barrier to effective treat...  Read More             
        
        
    Gender:
                FEMALE
            Ages:
                18 years and above
            Trial Updated:
                06/24/2025
            
            Locations: Hawaii Cancer Care Inc - Waterfront Plaza, Honolulu, Hawaii  +5 locations         
        
        
            Conditions: Anatomic Stage I Breast Cancer AJCC v8, Anatomic Stage II Breast Cancer AJCC v8, Anatomic Stage III Breast Cancer AJCC v8, HER2 Negative Breast Carcinoma, Hormone Receptor Positive Breast Carcinoma, Invasive Breast Carcinoma, Prognostic Stage I Breast Cancer AJCC v8, Prognostic Stage II Breast Cancer AJCC v8, Prognostic Stage III Breast Cancer AJCC v8
        
            
        
    
                
                                    Testing Low Dose Tamoxifen for Invasive Breast Cancer, the (LoTam) Trial
                                
            
            
        Recruiting
                            
            
                This phase III trial compares the effect of low dose tamoxifen to usual hormonal therapy, including aromatase inhibitors, in treating post-menopausal women with hormone positive, HER2 negative early stage breast cancer. Tamoxifen is in a class of medications known as antiestrogens. It blocks the activity of estrogen (a female hormone) in the breast. This may stop the growth of some breast tumors that need estrogen to grow. Aromatase inhibitors, such as anastrozole, letrozole, and exemestane, pre...  Read More             
        
        
    Gender:
                ALL
            Ages:
                18 years and above
            Trial Updated:
                06/24/2025
            
            Locations: Kaiser Permanente Moanalua Medical Center, Honolulu, Hawaii         
        
        
            Conditions: Anatomic Stage 0 Breast Cancer AJCC V8, Anatomic Stage 1 Breast Cancer AJCC V8, Anatomic Stage IIA Breast Cancer AJCC V8, Estrogen Receptor-Positive Breast Carcinoma, HER2-Negative Breast Carcinoma
        
            
        
    
                
                                    Testing the Addition of an Anti-Cancer Drug, Irinotecan, to the Standard Chemotherapy Treatment (FOLFOX) After Long-Course Radiation Therapy for Advanced-Stage Rectal Cancers to Improve the Rate of Complete Response and Long-Term Rates of Organ Preservation
                                
            
            
        Recruiting
                            
            
                This phase II trial compares the effect of irinotecan versus oxaliplatin after long-course chemoradiation in patients with stage II-III rectal cancer. Combination chemotherapy drugs, such as FOLFIRINOX (fluorouracil, irinotecan, leucovorin, and oxaliplatin), FOLFOX (leucovorin, fluorouracil, oxaliplatin, and irinotecan ), and CAPOX (capecitabin and oxaliplatin) work in different ways to stop the growth of tumor cells, either by killing the cells, by stopping them from dividing, or by stopping th...  Read More             
        
        
    Gender:
                ALL
            Ages:
                18 years and above
            Trial Updated:
                06/24/2025
            
            Locations: Hawaii Cancer Care Inc - Waterfront Plaza, Honolulu, Hawaii  +8 locations         
        
        
            Conditions: Locally Advanced Rectal Carcinoma, Stage II Rectal Cancer AJCC v8, Stage III Rectal Cancer AJCC v8
        
            
        
    
                
                                    Pembrolizumab vs. Observation in People With Triple-negative Breast Cancer Who Had a Pathologic Complete Response After Chemotherapy Plus Pembrolizumab
                                
            
            
        Recruiting
                            
            
                The phase III trial compares the effect of pembrolizumab to observation for the treatment of patients with early-stage triple-negative breast cancer who achieved a pathologic complete response after preoperative chemotherapy in combination with pembrolizumab. Immunotherapy with monoclonal antibodies, such as pembrolizumab, may help the body's immune system attack the cancer, and may interfere with the ability of tumor cells to grow and spread. This trial may help researchers determine if observa...  Read More             
        
        
    Gender:
                ALL
            Ages:
                18 years and above
            Trial Updated:
                06/24/2025
            
            Locations: Hawaii Cancer Care Inc - Waterfront Plaza, Honolulu, Hawaii  +6 locations         
        
        
            Conditions: Anatomic Stage I Breast Cancer AJCC v8, Anatomic Stage II Breast Cancer AJCC v8, Anatomic Stage III Breast Cancer AJCC v8, Early Stage Triple-Negative Breast Carcinoma
        
            
        
    121 - 132 of 204
            